Breast Cancer Research

Table 2 Analysis of DFS and OS

From: Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis

Outcome	Univariate			Multivariate*
Outcome	HR	95% CI	p-value	HR	95% CI	p-value
OS ALL**	0.7984	0.6253–1.0194	0.071	0.8061	0.6633–0.9795	0.03
OS HR +	0.9193	0.7506–1.1258	0.416	0.8255	0.7790–0.8748	< 0.001
OS TNBC	0.9869	0.7323–1.3300	0.931	0.9447	0.6356–1.4039	0.778
DFS ALL**	0.889	0.7106–1.1122	0.303	0.8317	0.7036–0.9832	0.031
DFS HR +	1.0047	0.8232–1.2262	0.963	0.8751	0.7451–1.0277	0.104
DFS TNBC	1.2086	0.6465–2.2592	0.553	0.9468	0.6758–1.3265	0.751

CI confidence interval; DFS disease-free survival; HR hazard ratio; TNBC triple-negative breast cancer
^*Adjusted by HER2 status, age, T stage, N stage, histopathological type, grading, and hormone receptor status
^**Complete OS and DFS data available in supplementary Figs. S2 and S3

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com